Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history‐friendly model

This paper is a first attempt at modelling the long-term dynamics of market structure and innovation in the pharmaceutical industry in a history-friendly way. The model examines the relationships between the nature of the search space, demand, the patterns of competition, and industry evolution in the age of random screening and in the age of molecular biology, and shows that concentration in the pharmaceutical industry is shaped by lack of cumulativeness in innovative activities and market fragmentation. The model conforms to our appreciative understanding and responds to changes in parameters concerning demand, costs, economies of scale, opportunity conditions and the relative advantages of new biotechnology firms (NBFs) vis-ý-vis incumbents. With the exception of cost increases, the model is quite robust to these changes in its essential features: it is quite difficult to raise substantially concentration and to have NBFs displacing incumbents. Copyright 2002, Oxford University Press.

[1]  Franco Malerba,et al.  Product Diversification in a “History-Friendly Model of the Evolution of the Computer Industry , 2001 .

[2]  R. Henderson,et al.  Public-private interaction in pharmaceutical research. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Meir Statman Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation , 1983 .

[4]  John Sutton,et al.  Technology and Market Structure: Theory and History , 1998 .

[5]  Richard R. Nelson,et al.  On limiting or encouraging rivalry in technical progress: The effect of patent scope decisions , 1994 .

[6]  Henry G. Grabowski,et al.  Innovation and Structural Change in Pharmaceuticals and Biotechnology , 1994 .

[7]  Ashish Arora,et al.  The Changing Technology of Technical Change , 1994 .

[8]  Massimo Riccaboni,et al.  Technological change and network dynamics: Lessons from the pharmaceutical industry , 2001 .

[9]  I. Cockburn,et al.  Measuring competence?: exploring firm effects in pharmaceutical research , 1994 .

[10]  L. Galambos,et al.  The pharmaceutical industry in the twentieth century: A reappraisal of the sources of innovation , 1996 .

[11]  A. Arora,et al.  The changing technology of technological change: general and abstract knowledge and the division of , 1994 .

[12]  F. Malerba,et al.  Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening , 2001 .

[13]  Louis Galambos,et al.  Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.

[14]  D. Teece Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[15]  Massimo Riccaboni,et al.  Innovation and corporate growth in the evolution of the drug industry , 2001 .

[16]  Franco Malerba,et al.  Competition and industrial policies in a ‘history friendly’ model of the evolution of the computer industry , 2001 .

[17]  Robert I. Chien Issues in pharmaceutical economics , 1979 .

[18]  R. Nelson,et al.  Economic Theories about the Benefits and Costs of Patents , 1998 .

[19]  S. Peltzman Regulation of pharmaceutical innovation : the 1962 amendments , 1974 .

[20]  Luigi Orsenigo,et al.  The emergence of biotechnology , 1989 .

[21]  D Schwartzman "Innovation in the Pharmaceutical Industry". , 1978, British medical journal.

[22]  Catherine Matraves,et al.  Market Structure, R&D and Advertising in the Pharmaceutical Industry , 2003 .

[23]  Rebecca Henderson,et al.  Sources of Industrial Leadership: The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change , 1999 .

[24]  G. Pisano The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry☆ , 1991 .

[25]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[26]  A. Arora,et al.  COMPLEMENTARITY AND EXTERNAL LINKAGES: THE STRATEGIES OF THE LARGE FIRMS IN BIOTECHNOLOGY* , 1990 .

[27]  Lacy Glenn Thomas,et al.  Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals , 1994 .